Anti-BCMA antibodies and their uses

Abstract

To provide an antibody or an antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof.SOLUTION: An antibody or an antigen-binding fragment thereof inhibits binding of BCMA protein with a substance that specifically binds to BCMA protein. The substance that specifically binds to BCMA protein is a B-cell activating factor (BAFF), a proliferation inducing ligand (APRIL), or a combination thereof. Provided also are pharmaceutical compositions for prevention or treatment of cancer, including the antibody or the antigen-binding fragment thereof.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to an antibody that specifically binds to B-cell maturation antigen (BCMA) protein, or an antigen-binding fragment thereof, a method for producing the same, and uses thereof.

Background Art

[0002] B-cell maturation antigen (BCMA) is a protein of approximately 20 kDa and belongs to the tumor necrosis factor receptor (TNFR) family of proteins. BCMA is known as a ligand for B-cell activating factor belonging to the tumor necrosis factor family (BAFF) and a proliferation inducing ligand (APRIL). In pathological situations, BCMA is expressed in the neoplastic plasma cells of patients with multiple myeloma (MM), and the survival rate of the multiple myeloma patient group decreases as the BCMA expression increases (Moreaux et al., Eur J Haematol 2009; 83: 119-129). Multiple myeloma is a neoplastic disease caused by monoclonal proliferation of plasma cells. Although the initial response rate has increased with the development of drugs such as thalidomide, bortezomib, and lenalidomide, and the development of treatment methods, the survival time has not yet been significantly improved. Recently, a monoclonal antibody targeting CD38 and CS-1 / SLAMF7 has been approved by the FDA as a treatment for multiple myeloma, but the effect is minimal in some groups, including relapsed / refractory multiple myeloma patients. In particular, CD38 is expressed not only on immune cells including lymphocytes but also on the surface of red blood cells, and it has been reported that various pre-transfusion tests show false positives when antibodies against CD38 are treated. Therefore, there is a need to develop a multiple myeloma treatment agent with fewer side effects and improved efficacy compared to existing drugs. BCMA, which shows restricted expression in normal cells and specific expression in pathological conditions, is considered to be one of the main target candidates for multiple myeloma therapeutics. Therefore, there is a need to develop antibodies that can specifically recognize BCMA and inhibit or regulate its function. Summary of the Invention [Problem to be solved by the invention]

[0003] The problem to be solved by the present invention is to provide an antibody or antigen-binding fragment thereof that specifically binds to BCMA. Another problem to be solved by the present invention is to provide a pharmaceutical composition for preventing or treating cancer associated with activation or overproduction of BCMA. Another problem to be solved by the present invention is to provide a method for producing an antibody or antigen-binding fragment thereof that specifically binds to BCMA. The problem to be solved by the present invention is also to provide a method for preventing or treating cancer associated with activation or overproduction of BCMA protein. [Means for solving the problem]

[0004] a heavy chain variable region comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 27 to 55; a light chain variable region comprising one or more amino acid sequences selected from the group consisting of SEQ ID NOs: 56 to 84, and SEQ ID NOs: 120 to 128; Alternatively, the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to B-cell maturation antigen (BCMA), comprising the heavy chain variable region and the light chain variable region. There are five types of heavy chains (γ, δ, α, μ, and ε), and the heavy chain determines the type of antibody. α and γ are composed of 450 amino acids, and μ and ε are composed of 550 amino acids. The heavy chain has two regions, namely, a variable region and a constant region. There are two types of light chains, λ and κ, which are composed of approximately 211 to 217 amino acids. Each human antibody has only one identical type of chain. The light chain is made up of a constant region and a variable region in succession. The variable region refers to the region of an antibody to which an antigen binds. The heavy chain variable region may comprise a complementarity determining region (CDR)-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 27 to 34; a CDR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 35 to 45; and a CDR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 46 to 55. The term "complementarity determining region (CDR)" refers to a site in the variable site of an antibody that confers binding specificity to an antigen. For example, the heavy chain variable region may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 to 15. The light chain variable region may comprise a CDR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 56-65, 120, 121, and 124-128, a CDR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 66-74, and a CDR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 75-84, and 122, 123. For example, the light chain variable region may comprise an amino acid sequence selected from the group consisting of SEQ ID NOs: 16-26, and 107-119. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 27, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 35, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 46, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 56, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 66, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 75. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 57, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 76. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 29, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 37, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 48, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 58, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 68, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 77. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 30, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 38, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 49, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 59, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 68, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 78. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 31, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 39, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 48, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 60, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 69, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 79. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 31, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 40, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 50, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 61, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 70, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 80. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 32, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 41, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 51, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 62, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 71, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 81. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 33, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 42, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 52, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 63, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 72, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 82. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 33, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 43, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 53, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 64, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 73, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 83. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 33, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 44, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 54, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 63, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 72, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 82. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 34, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 45, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 55, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 65, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 74, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 84. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 120, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 76. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 121, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 76. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 57, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 122. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 57, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 123. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 120, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 122. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 120, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 123. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 121, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 122. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 28, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 36, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 47, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 121, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 67, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 123. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 29, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 37, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 48, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 124, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 68, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 77. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 29, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 37, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 48, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 125, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 68, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 77. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 29, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 37, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 48, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 126, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 68, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 77. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 29, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 37, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 48, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 127, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 68, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 77. The antibody also comprises a CDR-H1 having an amino acid sequence consisting of SEQ ID NO: 29, a CDR-H2 having an amino acid sequence consisting of SEQ ID NO: 37, a CDR-H3 having an amino acid sequence consisting of SEQ ID NO: 48, a CDR-L1 having an amino acid sequence consisting of SEQ ID NO: 128, a CDR-L2 having an amino acid sequence consisting of SEQ ID NO: 68, and a CDR-L3 having an amino acid sequence consisting of SEQ ID NO: 77. Antibodies comprising one or more light chain CDRs of SEQ ID NOs: 120 to 128 also have improved target antigen-binding ability compared to the respective wild-type antibodies. The B cell maturation antigen (BCMA) is also a BCMA polypeptide or a fragment thereof. BCMA is also called TNFRSF17 (tumor necrosis factor receptor super family member 17), BCM, CD269, or TNFRSF13A, TNF receptor super family member 17. The BCMA polypeptide may comprise the human amino acid sequence of GenBank Accession No. NP_001183, or the mouse amino acid sequence of GenBank Accession No. NP_035738. The BCMA polypeptide may comprise the amino acid sequence encoded by the polynucleotide of GenBank Accession No. NM_001192 (human), or the polynucleotide of GenBank Accession No. NM_011608 (mouse). The fragment is also a polypeptide comprising a partial amino acid sequence of the BCMA polypeptide. The antibody or antigen-binding fragment thereof can specifically bind to any one of amino acids 1 to 54 from the N-terminus of SEQ ID NO:1. The antibody or antigen-binding fragment thereof can inhibit binding of a BCMA protein to a substance that specifically binds to the BCMA protein, also referred to as a ligand, such as B-cell activating factor belonging to the tumor necrosis factor family (BAFF), a proliferation inducing ligand (APRIL), or a combination thereof. The term "antibody" is used interchangeably with the term "immunoglobulin (Ig)". A complete antibody is a structure having two full-length light chains and two full-length heavy chains, each of which is linked to a heavy chain by a disulfide bond (SS-bond). The antibody may be, for example, IgA, IgD, IgE, IgG or IgM. The antibody may be a monoclonal or polyclonal antibody. The antibody may be an animal-derived antibody, a mouse-human chimeric antibody, a humanized antibody or a human antibody. The term "antigen-binding fragment" refers to a portion of a polypeptide that is a fragment of the entire immunoglobulin structure and contains a portion to which an antigen can bind. For example, the antigen-binding fragment is an scFv (scFv). 2 , Fv, Fab, Fab', FvF(ab') 2 , or a combination thereof. The antibody or antigen-binding fragment thereof may also be modified, for example, by conjugation or binding, glycosylation, deamidation, tagging, or a combination thereof. The antibody or antigen-binding fragment thereof may also be conjugated to other drugs, such as anti-cancer drugs. For example, the antibody or antigen-binding fragment thereof may be conjugated to horseradish peroxidase (HRP), alkaline phosphatase, hapten, biotin, streptavidin, fluorescent substances, radioactive substances, quantum dots, polyethylene glycol (PEG), histidine tags, or combinations thereof. The fluorescent substances may be Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 680, Alexa Fluor® 750, Alexa Fluor® 790, or Alexa Fluor® TM350. A pharmaceutical composition for preventing or treating cancer is provided, which comprises an antibody or antigen-binding fragment thereof that specifically binds to BCMA. The above-mentioned antibodies, antigen-binding fragments and BCMA are as described above. The cancer may be a disease associated with activation or overproduction of BCMA protein. The cancer may be a solid or non-solid cancer. A solid cancer is a cancer tumor that occurs in an organ such as the liver, lung, breast, or skin. A non-solid cancer is a cancer that occurs in the blood, and is also called blood cancer. The cancer may be multiple myeloma. The term "prevention" refers to any action of suppressing cancer or delaying its onset by administering the pharmaceutical composition, and the term "treatment" refers to any action of improving or favorably altering the symptoms of cancer by administering the pharmaceutical composition. The pharmaceutical composition may include a pharma- ceutically acceptable carrier. The term "carrier" is used to include excipients, diluents, or adjuvants. The carrier may be, for example, selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, water, saline, buffers such as PBS, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. The composition may include a filler, an anti-agglomerating agent, a lubricant, a wetting agent, a flavoring agent, an emulsifier, a preservative, or a combination thereof. The pharmaceutical composition can be prepared in any dosage form by a conventional method. The composition can be, for example, formulated into an oral dosage form (e.g., powder, tablet, capsule, syrup, pill or granule) or a parenteral dosage form (e.g., injection). The composition can also be prepared into a systemic or local dosage form. The pharmaceutical composition also includes an effective amount of the antibody or antigen-binding fragment thereof, the anti-cancer agent, or a combination thereof. The term "effective amount" refers to an amount sufficient to show a preventive or therapeutic effect when administered to an individual in need of prevention or treatment. The effective amount can be appropriately selected by a person skilled in the art depending on the cell or individual selected. It is also determined by factors including the severity of the disease, the age, weight, health condition, and sex of the patient, the sensitivity of the patient to the drug, the administration time, the administration route and excretion rate, the duration of treatment, the combination with the composition used, or the drug used simultaneously, and other factors well known in the medical field. The effective amount is also about 0.5 μg to about 2 g per pharmaceutical composition. The dosage of the pharmaceutical composition may be, for example, within the range of about 0.001 mg / kg to about 100 mg / kg on an adult basis. The administration may be once a day, multiple times a day, or once every 1 to 4 weeks, or once to 12 times a year. A method of preventing or treating cancer is provided that includes administering to an individual an antibody or antigen-binding fragment thereof that specifically binds to BCMA. The antibodies, antigen-binding fragments, BCMA, cancer, prevention and treatment are as described above. The individual may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat or cat. The individual may be any individual suffering from or at risk of suffering from a disease associated with activation or overproduction of the BCMA protein, such as cancer. The antibody or antigen-binding fragment thereof, anti-cancer agent, or combination thereof may be administered directly to an individual by any means, such as, for example, oral, intravenous, intramuscular, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration. The antibody or antigen-binding fragment thereof, anti-cancer agent, or combination thereof may also be administered systemically or locally, alone or in combination with other pharma- ceutical active compounds. The desired dosage of the antibody or its antigen-binding fragment, anticancer agent, or a combination thereof may vary depending on the patient's condition and weight, the severity of the disease, the drug form, the route of administration, and the duration of administration, and may be appropriately selected by those skilled in the art. The dosage may be, for example, within the range of about 0.001 mg / kg to about 100 mg / kg for an adult. The administration may be once a day, multiple times a day, once every week to every four weeks, or once to twelve times a year. Effect of the Invention

[0005] The antibody or antigen-binding fragment thereof that specifically binds to BCMA and uses thereof can be used to effectively prevent or treat cancer. [Brief description of the drawings]

[0006] [Figure 1A] This is a graph showing the results of ELISA measurement of the binding ability of the 1H antibody, the 2G antibody, and the 5G antibody to human BCMA or monkey BCMA. [Figure 1B]1 is a graph showing the results of ELISA measurement of the binding affinity of B58 antibody, 2C6 antibody, 5C3 antibody, 5B5 antibody, 5A6 antibody, 5D5 antibody, 2F8 antibody, and 4H9 antibody to human BCMA. [Figure 2A] This is a graph showing the binding affinity of selected antibodies to cell surface BCMA measured by FACS in H929 (multiple myeloma cells), OPM-2 (multiple myeloma cells), and CHOK1-hBCMA cell lines overexpressing human BCMA. [Figure 2B] This is a graph showing the binding affinity of selected antibodies to cell surface BCMA measured by FACS in Raji (B lymphocytic cancer cell line) and CHOK1 cell lines that do not express BCMA. [Diagram 3] 1 is a graph showing the results of ELISA measurement of the binding affinity of B58 antibody, 5A6 antibody, 5D5 antibody, and 5B5 antibody to human, monkey, mouse, and rat BCMA. [Figure 4] 1 is a graph showing the results of ELISA measurement of the binding affinity of B58 antibody, 5A6 antibody, 5D5 antibody, and 5B5 antibody to human BCMA receptor, human TACI receptor, and human BAFF receptor. [Figure 5A] This is a graph showing the results of competitive binding of B58 antibody to human BCMA together with other antibodies (Ref. Ab: J6MO antibody). [Figure 5B] This is a graph showing the results of competitive binding of the 5A6 antibody together with other antibodies to human BCMA. [Figure 5C] This is a graph showing the results of competitive binding of the 5B5 antibody to human BCMA together with other antibodies (Ref. Ab: J6MO antibody). [Figure 5D] This is a graph showing the results of competitive binding of the 5D5 antibody to human BCMA together with other antibodies (Ref. Ab: J6MO antibody). [Figure 6A] 1 is a graph showing the results of competitive binding between an APRIL ligand associated with human BCMA and an antibody. [Figure 6B]A graph showing the results of competitively binding BAFF ligand related to human BCMA and an antibody. [Figure 7] A graph showing the results of antibody - dependent cell cytotoxicity evaluation (ADCC) of B58 antibody, 5A6 antibody, 5D5 antibody, 5B5 antibody and 5A6(DANA) antibody in H929 cells and Raji cells. [Figure 8A] A graph showing the size (mm3) of tumors over time (time: days) after injection of multiple myeloma cell line H929. [Figure 8B] A graph showing the size (mm3) of tumors by antibody over time (time: days) after injection of multiple myeloma cell line H929. [Figure 8C] A graph showing the weight (g) of tumors by antibody over time (time: days) after injection of multiple myeloma cell line H929. [Figure 9A] A graph showing the size (mm3) of tumors over time (time: days) after injection of multiple myeloma cell line OPM - 2. [Figure 9B] A graph showing the size (mm3) of tumors by antibody over time (time: days) after injection of multiple myeloma cell line OPM - 2. [Figure 9C] A graph showing the weight (g) of tumors by antibody over time (time: days) after injection of multiple myeloma cell line OPM - 2. [Figure 10A] Results showing the binding affinity of mutant 5A6 and its wild - type antibody to the target antigen. [Figure 10B] Results showing the binding affinity of mutant 5D5 and its wild - type antibody to the target antigen. [Figure 10C] A graph measuring by FACS the binding affinity of mutant 5A6 and its wild - type antibody to the selected antibody against cell - surface BCMA. [Figure 10D] A graph measuring by FACS the binding affinity of mutant 5D5 and its wild - type antibody to the selected antibody against cell - surface BCMA. [Figure 11]This is a graph showing the binding avidity to recombinant human BCMA antigen using mutant 5A6 LM6, 5D5 LM4, and their respective wild-type antibodies. [Figure 12] 1 is a graph showing the results of antibody-dependent cellular cytotoxicity (ADCC) assay of mutant 5A6 LM6 and 5D5 LM4 with their respective wild-type antibodies. [Figure 13] This is a graph showing tumor size (mm3) over time (hours:days) when mice were injected with the multiple myeloma cancer cell line H929 and administered mutant 5A6 LM6, 5D5 LM4, and the respective wild-type antibodies. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] The present invention will be described in more detail below with reference to examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples. Example 1. Preparation of anti-BCMA antibodies 1. Antigen Production Antigens were prepared for the production of anti-BCMA antibodies as follows: antigens containing residues 5 to 54, residues 1 to 51, residues 1 to 54, and residues 4 to 48 from the N-terminus of the amino acid sequence of human BCMA (NP_001183.2, SEQ ID NO: 1) were used. Specifically, we prepared an antigen containing human BCMA residues 5 to 54 (Genscript®, Z02731) ("human BCMA(5-54)"), an antigen in which human BCMA1-51 (self-produced, expressed in CHO cells) was fused to the Fc region of human IgG1 ("human BCMA-Fc(1-51)"), a human BCMA1-51 antigen (10620-H03H, Sino Biological Inc.) fused to an Fc region and a His tag at the C-terminus ("human BCMA-Fc / His(1-51)"), and an antigen in which human BCMA4-48 (self-produced, expressed in HEK293 cells) was fused to the Fc region ("human BCMA-Fc(4-48)"). Human BCMA-Fc(4-48) was produced as follows. A polynucleotide encoding human BCMA residues 4 to 48 was cloned into pAB1-Fc, an animal cell expression vector containing a CMV promoter. The cloned vector was transformed into HEK293E cells, and human BCMA-Fc(4-48) was purified using protein A affinity chromatography. Human BCMA-Fc(1-51) was also produced by the same method. To confirm species cross-reactivity, we used rhesus BCMA(1-53) (90103-C02H, Sino Biological Inc.), mouse BCMA(1-49) (50076-M01H, Sino Biological Inc.), and rat BCMA(1-49) (80156-R01H, Sino Biological Inc.) fused with the Fc region of human IgG1. The amino acid sequences of rhesus BCMA(1-53), mouse BCMA, and rat BCMA are shown in Table 1 below. [Table 1] 2. Library phage preparation and phage display panning A human-derived ScFv (single-chain variable fragment) phage library cell (Mol. Cells OT, 225-235, February 28, 2009) capable of binding to various antigens was prepared. The prepared phage library was infected with helper phage, and phage packaging was induced. The culture was then centrifuged at 4,500 rpm at 4°C for 15 minutes, and 4% (w / v) PEG 6000 (Fluka, 81253) and 3% NaCl (Sigma, S7653) were added to the supernatant to dissolve it sufficiently, and then incubated on ice for 1 hour. The mixture was centrifuged again at 8,000 rpm at 4°C for 20 minutes, and the pellet was suspended in PBS and centrifuged again at 12,000 rpm at 4°C for 10 minutes to obtain a supernatant containing library phages. The obtained library phages were stored at 4°C until use. To screen for antibodies cross-reactive with human BCMA, human BCMA, and monkey BCMA, panning was performed three times in total as follows: 5 μg of the antigen prepared in Example 1.1 was added to an immunotube (Immunotube, maxisorp 444202) and incubated at 4° C. for 16 hours to coat the surface of the tube with the protein. The supernatant was removed, and bovine serum albumin (BSA) was added for blocking to block non-specific binding. 10 prepared in Example 1.2 12 The CFU phage library was mixed with 1.5% (w / v) BSA and added to an immunoassay tube coated with an antigen protein, and then reacted at 37°C for 1 hour to allow BCMA-specific phages to bind to the antigen. After multiple washings with PBS-T (phosphate buffered saline; 0.05% Tween 20) solution, BCMA-bound phages were collected using 100 mM triethylamine solution. The collected phages were neutralized with 1M Tris buffer (pH 7.4), infected with K12 ER2738 E. coli, and the process of collecting the phages was repeated four times to pan the phages. As the panning rounds progressed, the washing and collection using PBS-T was increased to amplify and concentrate the antigen-specific phages. 3. Single clone phage antibody selection To select monoclonal antibodies that specifically bind to BCMA from the phage pool, a monoclonal phage antibody selection process was performed. Specifically, the phage pool obtained in Example 1.2 was serially diluted and cultured in a solid medium containing LB-tetracycline / cabenicillin to obtain single colonies. Each colony was cultured in a 96-deep well plate until the OD600 reached 0.5 to 0.7. 20 MOI helper phage was added to the culture and reacted at 37°C for 1 hour. Kanamycin was then added to the culture and cultured overnight at 30°C. The next day, the culture was centrifuged to take the supernatant, which was then used to perform ELISA to select BCMA-specific phages. 100 ng of recombinant BCMA per well was coated on an ELISA plate, and the plate was coated with 3% BSA to prevent non-specific binding, and then washed with PBS. The prepared single clone phage was added to each well, incubated at 37°C for 1 hour, and the plate was washed three times with PBS-T. ELISA was performed using horseradish peroxidase (HRP)-conjugated anti-HA (hemagglutinin) antibody and TMB (tetramethylbenzidine, Sigma, T0440). Clones with absorbance at 450 nm of 0.5 or more and 5-fold increase in absorbance compared to the control group containing anti-HA HRP alone were selected. Eleven antibody clones (B58, 5A6, 5D5, 5B5, 2C6, 2F8, 4H9, 1H, 2G, 5G, and 5C3) that specifically bind to human BCMA were selected. From the nucleic acid sequences encoding the selected antibodies, the amino acid sequences of the antibody heavy chain variable region (SEQ ID NOs: 5 to 15) and the light chain variable region (SEQ ID NOs: 16 to 26) were analyzed to determine the complementarity determining regions (CDRs) according to the Kabat definition. The determined heavy and light chain CDR amino acid sequences (N→C) are shown in Tables 2 and 3, respectively. [Table 2] [Table 3] The nucleic acid sequences encoding the heavy chain variable region and the light chain variable region are shown in Table 4 below. [Table 4] 4. Production of Anti-BCMA IgG Antibodies from Selected Anti-BCMA Phage Polynucleotides having nucleic acid sequences encoding the antibodies selected in Example 1.3 were synthesized. The prepared polynucleotides were cloned into vectors for animal cell culture (heavy chain expression vector: pAB1-HC, light chain expression vector: pAB1-LC). A total of 22 vectors containing polynucleotides encoding heavy and light chains were prepared for the 11 antibody clones (B58, 5A6, 5D5, 5B5, 2C6, 2F8, 4H9, 1H, 2G, 5G, and 5C3). The prepared vectors contained IgG1 type sequences. CHO-S cells were cultured in CD-CHO (Gibco, 10743) medium, and the prepared vector was introduced into the CHO-S cells using polyethyleneimine (PEI). The transduced CHO-S cells were cultured in CD-CHO medium under conditions of 8% CO2, 37°C, and 110 rpm for about 7 days. The prepared CHO-S cell culture was passed through a MabSelect SuRe column (GE Healthcare, 5 ml) equilibrated with equilibration buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl) to allow the expressed antibodies to bind to the column. The antibodies were eluted with a solution of 50 mM Na-citrate (pH 3.4) and 100 mM NaCl, and then neutralized with 1 M Tris-HCl (pH 9.0) to a final pH of 7.2. The buffer was then exchanged with PBS (pH 7.4), and the anti-BCMA IgG antibodies B58, 5A6, 5D5, 5B5, 2C6, 2F8, 4H9, 1H, 2G, 5G, and 5C3 were stored at 4° C. until use. 5. Construction of 5A6 and 5D5 Mutants To improve the productivity of the selected 5A6 and 5D5 antibodies, mutant antibodies were produced by mutating one or two amino acid residues in the light chain CDR of the antibody using the nucleic acid sequences in Table 4. The amino acid sequences of CDR-L1, CDR-L2 and CDR-L3 in the light chain variable region of the 5A6 mutant antibody (SEQ ID NOs: 107 to 114) and the light chain variable region of the 5D5 mutant antibody (SEQ ID NOs: 115 to 119) are shown in Tables 5 and 6, respectively. In Tables 5 and 6, the amino acid residues underlined and in bold are the mutated portions (WT: wild type, LM: light chain mutation). [Table 5] [Table 6] Example 2. Kinetic analysis of anti-BCMA IgG antibodies 1. Confirmation of the binding ability of anti-BCMA IgG antibodies to BCMA (1) Confirmation of binding ability to recombinant BCMA The specific binding ability of the anti-BCMA IgG antibodies isolated in Example 1.4 to recombinant BCMA protein was analyzed by ELISA. Recombinant human BCMA or monkey BCMA was used as the antigen, and HRP-conjugated Fab multiclonal antibody reagent (Pierce, 31414) was used as the secondary antibody, and ELISA was performed as described in Example 1.3. Absorbance at 450 nm as a function of antibody concentration is shown in Figures 1A and 1B. Figure 1A is a graph showing the binding ability of 1H, 2G, and 5G antibodies to human BCMA or monkey BCMA, and Figure 1B is a graph showing the binding ability of B58, 2C6, 5C3, 5B5, 5A6, 5D5, 4H9, and 2F8 antibodies to human BCMA. As can be seen from Figure 1A, the 1H, 2G and 5G antibodies bound to human BCMA and monkey BCMA in a concentration-dependent manner. The binding strength to human BCMA was highest in the order of 2G, 1H and 5G, and the binding strength to monkey BCMA was highest in the order of 1H, and was at the same level for 2G and 5G. As can be seen from Figure 1B, it was confirmed that all eight types of anti-BCMA antibodies (B58, 2C6, 5C3, 5B5, 5A6, 5D5, 4H9 and 2F8) bound to human BCMA in a concentration-dependent manner. (2) Confirmation of binding ability to BCMA on the cell surface The extent to which the selected anti-BCMA IgG antibodies bound to cell surface expressed BCMA was analyzed via a FACS system. Multiple myeloma cancer cells, H929 (ATCC, CRL-9068), which are known to express BCMA, were used. TM ) and OPM-2 cell lines (DSMZ, ACC50), and the CHOK1-hBCMA cell line (ABIBio) in which human BCMA is overexpressed were prepared. As a comparison group, the CHOK1 (ATCC, CRL-9618) and Raji (B-lymphocyte cancer cell line) (ATCC, CCL-86TM) cell lines, which do not express BCMA, were used. The seven IgG antibodies (B58, 5A6, 5D5, 5B5, 1H, 2G, and 5G) purified in Example 1.4 were added to the prepared cells at 10 μg / ml, incubated at 4° C. for 1 hour, and then washed twice with PBS buffer. Anti-human FcFITC was diluted 1:400, incubated at 4° C. for another 1 hour, and washed with PBS buffer. The fluorescence intensity of the cells was measured using a FACSCalibur instrument and is shown in Figures 2A and 2B (MFI: Mean Fluorescence Intensity). As can be seen from Figures 2A and 2B, it was confirmed that all of the selected antibodies specifically bind to BCMA expressed on the cell surface, but do not bind to cells that do not express BCMA. Therefore, it was confirmed that the selected antibodies have specific binding ability not only to recombinant BCMA protein, but also to the extracellular domain of BCMA expressed on the cell surface, and that the anti-BCMA antibodies can be used to selectively target BCMA-expressing cancer cell lines. 2. Analysis of the affinity of anti-BCMA IgG antibodies to human BCMA and monkey BCMA The affinity of the 11 selected anti-BCMA antibodies to human and monkey BCMA was analyzed. A 96-well black microplate was placed in a biosensor tray case, 200 μl of 1XKB was added to each of eight wells, and eight Ni-NTA biosensors (Fortebio) were inserted and hydration was performed for 10 minutes. For antigen immobilization, 5 μg / ml recombinant human BCMA-His (Sino Biological Inc.) was diluted with 1XKB. The experiment was performed with a threshold fixed at 0.5 to 1.0 nm, and Octet Data Acquisition 9.0 software was activated and an Octet program template was created. The first step was baseline 1, the second step was the loading step, and the threshold was fixed at 0.5 to 1.0 nm. The third step was baseline 2, and the association process was performed for 5 minutes and the dissociation process for 20 minutes. The plate temperature was fixed at 30°C, and the prepared buffers were added to a new 96-well black microplate in the correct order according to the Octet program template. 200 μl of recombinant human BCMA-Fc / His was diluted to 5 μg / ml and added as the antigen to be loaded to 200 μl of 1XKB used as baseline 1. After adding 200 μl of 1XKB used as baseline 2, 200 μl of the antibody to react with the antigen was dispensed and the instrument was operated. After the experiment was completed, the adsorption rate constant (kon: association constant), dissociation rate constant (kdis: dissociation constant) and equilibrium dissociation constant (KD: equilibrium dissociation constant) for each antibody were analyzed and calculated using Octet Analysis 9.0 software, and the contents are shown in Table 7. [Table 7] As can be seen from Table 7, the affinity of the B58 antibody and the 5A6 antibody is about 10 -11 and the 2C6 antibody, the 5B5 antibody, and the 5D5 antibody have a KD value of about 10 -10It was confirmed that the selected antibodies have high binding affinity to human BCMA protein. Among them, 2C6 antibody, which has a weak binding affinity to human BCMA on the cell surface, and B58 antibody, which has no affinity to monkey BCMA, were excluded, and the affinity to monkey BCMA was further confirmed using three antibodies (5A6, 5B5, and 5D5), and the results are shown in Table 8. [Table 8] As can be seen from Table 8, it was confirmed that the 5A6 antibody, 5B5 and 5D5 antibody have high affinity not only for human BCMA but also for monkey BCMA. 3. Species cross-reactivity analysis of anti-BCMA antibodies The interspecies cross-binding of the selected antibodies B58, 5A6, 5D5 and 5B5 was analyzed by ELISA. 100 ng of human, monkey, mouse and rat BCMA antigens prepared in Example 1.1 were coated on the bottom of the plate, and then coated with 3% BSA to block non-specific binding. ELISA analysis was performed as described in Example 1.3 using the selected anti-BCMA IgG antibody as the primary antibody and anti-human Fab HRP (1:20,000 dilution) as the secondary antibody. The absorbance at 450 nm measured by a microplate reader is shown in Figure 3, and the 50% maximum effective concentration (EC 50 The effective concentrations (nM) of the respective compounds are shown in Table 9. [Table 9] As can be seen from Figure 3 and Table 9, the B58 antibody has binding affinity only to human BCMA, and the 5A6 antibody has binding affinity to both human and monkey BCMA. The 5D5 and 5B5 antibodies were analyzed and confirmed to have binding affinity to all species of BCMA (human, monkey, mouse, and rat). 4. Confirmation of BCMA specificity of anti-BCMA IgG BCMA is known to be involved in the maturation process of B cells, and TACI and BAFF receptors are known to be involved in the maturation process. The selected antibodies were analyzed via ELISA technique to determine whether they bind to BCMA-related proteins. Specifically, human BCMA-Fc (R&D Systems, 193-BC-050), TACI-Fc (R&D Systems, 174-TC) and BAFF-receptor (R&D Systems, 1162-BR) were diluted with PBS buffer and coated on an ELISA plate at 100 ng per well. The selected anti-BCMA IgG antibody was used as the primary antibody, and anti-human Fab HRP (1:20,000 dilution) was used as the secondary antibody, and ELISA analysis was performed as described in Example 1.4(1). Anti-BCMA monoclonal antibody J6MO (GSK) was used as a comparison group. The absorbance at 450 nm measured by a microplate reader is shown in Figure 4. As can be seen from Figure 4, the B58, 5A6, 5D5 and 5B5 antibodies did not bind to the TACI receptor or the BAFF receptor, but only bound to BCMA. Therefore, it was confirmed that the four selected anti-BCMA antibodies, B58, 5A6, 5D5 and 5B5, specifically bind to BCMA. 5. Relative comparison of epitopes of anti-BCMA antibodies The four selected antibodies (IgG) were used to analyze the competitive binding ability of the selected antibodies to human BCMA in order to compare their relative BCMA-binding sites. As described in Example 2.2, the binding ability between antibodies was analyzed using the Octet analysis system. The first step in the Octet program template was baseline 1, the second step was loading, and the threshold was fixed at 0.3 nm. The third step was the baseline. The fourth and fifth steps were reacted with each antibody, and the time was set to 10 minutes. In accordance with the Octet program template, the buffers prepared in a new 96-well black microplate were placed in the appropriate order. 200 μl of 1XKB used as baseline 1 was placed. Recombinant human BCMA (fused with Fc tag and His tag), which is the antigen to be loaded, was diluted to 5 μg / ml and placed in 200 μl each. 200 μl of 1XKB used as baseline 2 was placed. 200 μl of the antibody that first binds to the antigen was placed in 200 μl each. 200 μl of the second antibody was placed in 200 μl each. The temperature of the experimental plate was fixed at 30°C. After all the samples were added, the instrument was run. After the experiment was completed, the competition between the first and second antibodies was analyzed using Octet analysis 9.0 software, and the results are shown in Figure 5A to Figure 5D (Ref. Ab: J6MO antibody). As can be seen from Figures 5A to 5D, it was confirmed that the B58 antibody and the 5A6 antibody have different antigen-binding sites, i.e., epitopes, and that the 5B5 antibody and the 5D5 antibody have the same epitope. In addition, it was confirmed that the epitopes of the 5B5 antibody and the 5D5 antibody are partially identical to the epitope of B58. Therefore, it was confirmed that the four selected antibodies have diverse binding sites to the antigen BCMA. Example 3. Effect of anti-BCMA IgG antibody on cancer cells 1. Neutralizing effect of anti-BCMA IgG antibodies The ability of the selected anti-BCMA antibodies to block the binding of BCMA to its ligands (APRIL and BAFF) was confirmed by an ELISA-based solution competition assay. Specifically, human BCMA-Fc (R&D Systems, 193-BC-050) was diluted with PBS buffer and coated on an ELISA plate at 100 ng per well. After coating, the plate was emptied, and 100 μl of PBST containing 1% BSA was added to each well and incubated at 37°C for 2 hours. The antibody diluted to a concentration of 50 μg / ml or 0.00028 μg / ml was mixed with 10 ng / ml APRIL protein (R&D, 5860-AP-010 / CF) or 200 ng / ml BAFF (R&D, 2149-BF-010 / CF). IgG1 antibody was used as a negative control group, and J6MO antibody was used as a comparison group. Anti-HA-HRP (Roche, 12013819001) or anti-His-HRP (Roche, 11965085001) was used as the secondary antibody, and ELISA analysis was performed as described in Example 1.4(1). Anti-BCMA monoclonal antibody J6MO (GSK) was used as a comparison group. Absorbance at 450 nm was measured, and the results are shown in Figure 6A and Figure 6B. As can be seen from Figures 6A and 6B, it was confirmed that the B58 antibody effectively inhibits the binding of BCMA to BAFF and also interferes with the binding of BCMA to APRIL. It was confirmed that the 5A6 antibody, the 5B5 antibody, and the 5D5 antibody cannot inhibit the binding ability of APRIL to BCMA, but partially inhibit the binding ability of BAFF. Therefore, it was confirmed that the selected antibodies have different binding sites to the target antigen BCMA and have different levels of inhibition of BCMA ligand binding ability, but they may regulate and inhibit ligand binding, thereby effectively inhibiting cancer cell growth. 2.Antibody-dependent cell-mediated cytotoxicity (ADCC) of anti-BCMA IgG antibody The antibody-dependent cellular cytotoxicity of the selected antibodies was measured using an ADCC bioassay core kit (Promega, G0718). Specifically, H929 (ATCC, CRL-9068), which expresses a large amount of human BCMA, TM ) and the less expressed Raji (ATCC, CCL-86 TM) were used as target cells. As anti-BCMA antibodies, B58 antibody, 5A6 antibody, 5D5 antibody, and 5B5 antibody were prepared. In addition, to induce functional inhibition of the Fc portion involved in antibody-dependent cellular cytotoxicity and to use as a negative control, we prepared a 5A6 DANA mutant antibody in which the amino acid residue at aspartic acid at position 265 in the 5A6 Fc portion was replaced with alanine ("D265A") and the asparagine residue at position 297 was replaced with alanine ("N297A") (Cancer Cell, vol. 19, issue 1, pp. 101-113). ADCC analysis buffer was prepared by adding RPMI / 1640 (Promega, G708A) and 4% low IgG serum (Promega, AX20A). H929 and Raji cell lines resuspended in ADCC analysis buffer were added to a 96-well plate (white, flat bottom, Corning, CLS3917) at 5,000 cells (25 μl) per well. Anti-BCMA antibodies were prepared by serially diluting 1 / 8 starting from 133.3 nM (20 μg / ml) in ADCC analysis buffer. 25 μl of the prepared antibody was added to each well. After 3.6 ml of ADCC analysis buffer was placed in a 15 ml tube, an ADCC Bioassay Effector cell (Promega, G701A) was removed from the liquid nitrogen tank and rapidly thawed in a 37°C bath, and then poured into the 15 ml tube containing the ADCC analysis buffer. After thoroughly mixing the effector cells, carefully add 25 μl to each tube and incubate at 37°C, 5% CO 2 The cells were cultured for about 6 hours under the conditions described above. TM Luciferase assay buffer (Promega, G720A) was dissolved at room temperature and then incubated with Bio-Glo TM Add luciferase assay substrate (Promega, G719A), mix thoroughly, and then mix with Bio-Glo TM Luciferase assay reagent was prepared. After cell culture, the 96-well plate was left at room temperature for about 10 minutes, and then 25 μl of Bio-Glo was added to each well. TMLuciferase assay reagent was carefully added. After leaving it at room temperature for 5 minutes, the luminescence intensity was measured using a PHERAstar FS BMG LABTECH instrument. The results were analyzed using nonlinear regression analysis (curve fit) using GraphPad Prism, and the results are shown in Figure 7. As can be seen from FIG. 7, the selected anti-BCMA antibodies induced antibody-dependent cellular cytotoxicity in a concentration-dependent manner in H929 cells with high BCMA expression (B58>5A6=5D5>5B5). In the case of the 5A6 DANA mutant antibody that induced functional inhibition of the Fc region, ADCC was not induced, confirming that ADCC is caused by the Fc region of the antibody. On the other hand, ADCC was not induced for Raji, where BCMA expression was not observed. Therefore, it was confirmed that the selected B58, 5A6, 5D5, and 5B5 antibodies can specifically bind only to cancer cells expressing BCMA and induce antibody cytotoxicity due to Fc function. 3. Evaluation of tumor growth inhibition by anti-BCMA IgG antibodies in mouse models implanted with cancer cell lines (1) Evaluation of tumor growth inhibition in a mouse model implanted with the multiple myeloma cancer cell line H929 Six-week-old male CB17-SCID mice were used in the animal experiments after a 7-day acclimation period. Before cell transplantation, the hair at the mouse cell transplantation site was removed, and ear tags were attached to the ears for individual identification. On the day of cell transplantation, the multiple myeloma cancer cell line H929 cells cultured to meet the conditions were harvested and counted / viable in PBS using a Beckman Coulter. Finally, the number of cells administered per 100 μl of PBS (1x10 7 The cells were prepared so that the total volume was 1000 cells / mouse. Matrigel (BD) was added in the same volume as the cell suspension and mixed with a pipette. Mice were anesthetized with isoflurane inhalation, and 200 μl of the cell suspension was administered subcutaneously to the right back side, where hair had been removed. The mice were placed in a cage, and after waking up from anesthesia, a final check was made to see whether there were any problems with their activity. The tumor size was measured using callipers along the long and short axes of the tumor, and the final tumor size was calculated using the following formula 1. (Number 1) Tumor size (mm3 )=(0.5)x(major axis)x(minor axis) 2 Drug administration was performed on tumors with an average size of 269 mm 3 Administration began when the mice were 100-200 cm-long. The drugs were administered in five groups (n=7 each): a control group (PBS) and four types of anti-BCMA IgG antibodies (B58, 5A6, 5D5, and 5B5). The drugs were prepared at 2 mg / ml (20 g standard: 100 μl / head). The dose was 10 mg / kg, and the drugs were administered intravenously into the tail twice a week for a total of five times. Body weight was measured using an animal weighing scale. Body weight and tumor size were measured twice a week. On the 21st day after drug administration, the mice were euthanized after body weight and tumor size measurements, and the tumors of each individual were removed and weighed. Tumor size (mm) over time (days) after tumor injection 3 ), tumor size by antibody (mm 3 The tumor volume reduction rate (%) and tumor weight reduction rate (%) for each antibody compared to the control group are shown in Table 10 (p<0.001). [Table 10] As can be seen from Figures 8A to 8C and Table 10, in the H929 xenograft mouse model, the groups administered with four anti-BCMA IgG antibodies (B58, 5A6, 5D5, and 5B5) showed a tumor growth inhibitory effect compared to the control group (PBS). As a result of final analysis of the tumor size of each group, the tumors in the antibody-treated groups of the present application were reduced by about 51.7% to about 67.4% compared to the tumor size of the control group. As a result of one-way variance analysis, statistical significance was shown in the four anti-BCMA IgG antibodies compared to the control group (PBS) (p<0.001). Therefore, it was demonstrated that tumor growth can be significantly inhibited when the antibody selected for multiple myeloma is treated. In addition, 5D5 and 5A6 showed lower activity compared to B58 antibody in the antibody-dependent cytotoxicity evaluation or BCMA-associated ligand binding interference results, but showed an effect equal to or greater than B58 in the in vivo activity evaluation. This means that the two antibodies recognize epitopes that are advantageous for inhibiting tumor growth, or that the antibodies themselves have excellent physical properties. (2) Evaluation of tumor growth inhibition in a mouse model implanted with the multiple myeloma cancer cell line OPM-2 As described in Example 3.3(1), mice were implanted with the multiple myeloma cancer cell line OPM2, and tumor growth inhibition by antibody administration was evaluated. Drug administration was performed on tumors with an average size of 172 mm 3 Administration began when the mice were 10-20 cm in diameter. The drugs were administered in four groups (n=9 each): a control group (PBS) and four types of anti-BCMA IgG antibodies (B58, 5A6, and 5D5). The drugs were prepared at 2 mg / ml (20 g standard: 100 μl / head) so that the administration dose was 10 mg / kg. The administration dose was 10 mg / kg, and the mice were intravenously administered into the tail twice a week for a total of five times. On the 27th day after drug administration, the mice were euthanized after their body weight and tumor size were measured, and the tumors were removed from each mouse and weighed. Tumor size (mm) over time (days) after tumor injection 3 ), tumor size by antibody (mm 3 9A to 9C show the tumor volume reduction rate (%) and tumor weight reduction rate (%) for each antibody compared to the control group (p<0.001). [Table 11] As can be seen from Figures 9A to 9C and Table 11, in the OPM-2-implanted mouse model, the groups administered with three types of anti-BCMA IgG antibodies (B58, 5A6, and 5D5) showed a tumor growth inhibitory effect compared to the control group (PBS). As a result of final analysis of the tumor size of each group, the tumor inhibition level of each group compared to the control group was measured as 42.5% for B58, 35.4% for 5A6, and 38.5% for 5D5, respectively, and when measured for weight, the weight reduction rate was 41.4% for B58, 35.1% for 5A6, and 40.5% for 5D5, respectively, compared to the control group. As a result of one-way ANOVA, the anti-tumor effect of the three types of anti-BCMA IgG was statistically significant (p<0.001) compared to the control group, and no statistically significant difference was observed in the tumor size and tumor weight between the three antibodies. As can be seen from Figures 6 and 7, 5D5 and 5A6 showed lower activity than B58 antibody in the antibody-dependent cellular cytotoxicity evaluation or BCMA-associated ligand binding interference analysis, but showed the same level of effect as B58 in the in vivo efficacy evaluation, which means that the two antibodies may recognize epitopes that are advantageous for tumor growth inhibition or may have excellent physical properties themselves. 4. Confirmation of binding ability of mutated 5A6 and 5D5 to the target antigen (1) Confirmation of binding ability of wild-type 5A6, 5D5 and mutant 5A6, 5D5 to recombinant BCMA As described in Example 1.5, mutations were introduced into the anti-BCMA antibody 5A6 and the anti-BCMA antibody 5D5, and eight mutant antibodies from 5A6 and five mutant antibodies from 5D5 were produced and purified. These were analyzed for their binding to the recombinant proteins together with the respective wild-type antibodies, and the results are shown in Figures 10A and 10B. As can be seen from Figures 10A and 10B, six of the eight mutant antibodies from 5A6 (5A6 LM1, 5A6 LM3, 5A6 LM4, 5A6 LM5, 5A6 LM7, and 5A6 LM8) had the same or lower binding activity compared to the wild type, while two antibodies (5A6 LM2 and 5A6 LM6) showed increased antigen binding activity compared to the wild type. In the case of 5D5, two of the five mutant antibodies (5D5 LM1 and 5D5 LM2) had reduced antigen binding activity compared to the wild type 5D5, while the remaining three (5D5 LM3, 5D5 LM4, and 5D5 LM5) showed antigen binding activity equivalent to that of the wild type 5D5. The 50% maximum effective concentration (EC 50 The effective concentrations (nM) of the respective compounds are shown in Table 12. [Table 12] (2) Confirmation of binding ability of wild-type 5A6, wild-type 5D5, and their mutants to cell surface BCMA The binding avidity of the wild-type antibody and its mutant antibodies to cell surface antigens was compared. Wild-type 5A6 antibody, wild-type 5D5 antibody, and their mutant antibodies were added to multiple myeloma cancer cell H929 (ATCC, CRL-9068TM) in which BCMA is highly expressed, and the cell surface binding level of the antibodies was measured by FACS analysis. The fluorescence intensity of the cell surface was measured, and the results are shown in Figure 10C and Figure 10D. The mean fluorescence intensity (MFI) of each antibody is shown in Table 13. [Table 13] As can be seen from Figure 10C, Figure 10D and Table 13, in the case of 5A6, the cell binding ability of five mutant antibodies (5A6 LM1, 5A6 LM3, 5A6 LM4, 5A6 LM5 and 5A6 LM6) was increased compared to that of the wild-type 5A6 antibody. In addition, the cell binding ability of two mutant antibodies of 5D5 (5D5 LM4 and 5D5 LM5) was definitely increased compared to that of the wild-type 5D5 antibody. Therefore, it was confirmed that the binding ability to recombinant BCMA and cell surface BCMA was partially improved by partial modification of the CDR amino acids of the wild-type antibody. (3) Affinity analysis of 5A6 LM6 and 5D5 LM4 for human BCMA The target antigen binding affinity of 5A6 LM6 and 5D5 LM4, which bind to monomeric human BCMA antigen, was analyzed with their respective wild-type antibodies. Specifically, the prepared antibodies were diluted using 1x HPS-EP buffer (GE Healthcare, BR-1006-69). Target antigen binding affinity analysis was performed using Biacore T200 (GE Healthcare). Protein A chips were run with a contact time of 60 seconds, a stabilization time of 30 seconds, and a flow rate of 30 μl / min, so that the capture level reached 128 RU (response unit), and the antibody was captured on the protein A chip. The antigen was diluted two-fold from 100 nM to 6.25 nM using 1x HPS-EP buffer to prepare a total of six samples, and 1x HPS-EP buffer was used as a negative control (blank). The antigen prepared on the protein A chip with the captured antibody was flowed at a flow rate of 30 μl / min with a binding time of 60 s and a dissociation time of 180 s. Regeneration was performed using 10 mM glycine-HCL, pH 1.5 buffer (GE Healthcare, BR-1003-54) at a flow rate of 30 μl / min and a contact time of 30 s. A graph showing the response (RU: response unit) versus reaction time (seconds) is shown in FIG. 11, and the target antigen-binding affinity of the antibody calculated therefrom is shown in Table 14. [Table 14] As can be seen from FIG. 11 and Table 14, 5A6 LM6 had a lower dissociation rate after binding to BCMA compared to wild-type 5A6. 5D5 LM4 had an increased association rate with BCMA compared to wild-type 5A6. Therefore, it was confirmed that the 5A6 LM6 antibody and the 5D5 LM4 antibody have improved target antigen affinity compared to their respective wild-type antibodies. 5. Antibody-dependent cellular cytotoxicity (ADCC) assessment of 5A6 LM6 and 5D5 LM4 To compare the antibody-dependent cellular cytotoxicity of 5A6 LM6 and 5D5 LM4 with their respective wild-type antibodies, the measurements were performed using the method described in Example 3.2, and the measured antibody-dependent cellular cytotoxicity (ADCC) results are shown in Figure 12. As can be seen from Figure 12, the 5A6 LM6 antibody and the 5D5 LM4 antibody showed a higher level of antibody-dependent cellular cytotoxicity against the BCMA highly expressing cell line H929 than the wild-type antibody (left side of Figure 12). On the other hand, not only the 5A6WT antibody and the 5D5WT antibody, but also their mutant antibodies were unable to induce antibody-dependent cellular cytotoxicity against the BCMA non-expressing Jurkat cell line (right side of Figure 12). Furthermore, the 5A6NA and 5D5NA mutations, which are mutant antibodies that induce functional inhibition of the Fc region from the wild-type antibody, did not induce antibody-dependent cellular cytotoxicity against the BCMA-highly expressing H929 cell line (Figure 12, left side). Thus, the 5A6 LM6 antibody and the 5D5 LM4 antibody exhibited enhanced ability to induce BCMA-dependent cytotoxicity compared to their respective wild-type antibodies, which is consistent with the increase due to improved antigen binding demonstrated in Example 3.4, thereby demonstrating that the mutant 5A6 LM6 antibody and the 5D5 LM4 antibody can induce more effective cancer cell growth inhibition than their respective wild-type antibodies. 6. Evaluation of tumor growth inhibition by 5A6 LM6 antibody or 5D5 LM4 in mouse models transplanted with cancer cell lines In a severe combined immunodeficiency (SCID) mouse model, human myeloma NIH-H929 cells highly expressing BCMA were injected into the flank of the mouse at a dose of 1x10 7 We transplanted cells per head to create mice with human cancer tumors. After transplantation, the average tumor size was 180 mm 3 When the incubation period reached 10 days, group separation was performed (first day). A total of five antibodies, including the mutated 5A6 LM6 antibody and 5D5 LM4 antibody, their wild-type antibodies 5A6WT and 5D5WT, and a negative control human IgG1 (InVivo Plus human IgG1 isotype control, BioXCell), were administered twice a week at 10 mg / kg each into the tail vein using a 1 mL syringe for a total of four times (days 1, 4, 7, and 11). After the first administration, the size of the tumor implanted in the mice and the body weight were measured twice a week using a digital caliper and an animal scale (days 1, 4, 7, 11, 18, 22, and 25). Two weeks after the end of the administration of the experimental substances (day 25), the mice were 2 The mice were sacrificed using gas, and the tumors were excised, and the volume and weight of the excised tumors were measured. The tumor volume over time is shown in Figure 13, and the tumor volume reduction rate (%) and tumor weight reduction rate (%) of the treatment group compared to the negative control group are shown in Table 15. [Table 15] As can be seen from Figure 13, the four anti-BCMA antibodies (5A6WT, 5A6 LM6, 5D5WT, and 5D5 LM4) significantly reduced tumor growth compared to the negative control human IgG1 antibody. Also, as can be seen from Table 15, the four administered anti-BCMA antibodies showed statistical significance in terms of tumor cell growth inhibition rate (TGI%: % of tumor growth inhibition) compared to the negative control group (one-way ANOVA, P value < 0.05). However, the tumor size reduction was analyzed to be comparable between the wild-type antibody and its mutant antibody (5A6WT vs. 5A6 LM6, and 5D5WT vs. 5D5 LM4), and there was no statistical significance between the groups. As a result, the mutant 5A6 LM6 antibody and 5D5 LM4 antibody showed increased in vitro activity (target antigen binding ability and antibody-dependent cellular cytotoxicity induction) compared to their respective wild-type antibodies, but in vivo activity evaluation confirmed that they had the same level of cancer cell growth inhibition ability as their respective wild-type antibodies.

Claims

1. (1) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 127; CDR-L2 comprising the amino acid sequence of SEQ ID NO:68, and an antibody comprising a CDR-L3 comprising the amino acid sequence of SEQ ID NO:77; (2) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 124; CDR-L2 comprising the amino acid sequence of SEQ ID NO:68, and an antibody comprising a CDR-L3 comprising the amino acid sequence of SEQ ID NO:77; (3) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 125; CDR-L2 comprising the amino acid sequence of SEQ ID NO:68, and an antibody comprising a CDR-L3 comprising the amino acid sequence of SEQ ID NO:77; (4) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 126; CDR-L2 comprising the amino acid sequence of SEQ ID NO:68, and an antibody comprising a CDR-L3 comprising the amino acid sequence of SEQ ID NO:77; (5) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48; CDR-L1 comprising the amino acid sequence of SEQ ID NO: 128; CDR-L2 comprising the amino acid sequence of SEQ ID NO:68, and An antibody comprising a CDR-L3 comprising the amino acid sequence of SEQ ID NO:77; and (6) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29; CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37; CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48; CDR-L1 comprising the amino acid sequence of SEQ ID NO:58; CDR-L2 comprising the amino acid sequence of SEQ ID NO:68, and An antibody comprising a CDR-L3 comprising the amino acid sequence of SEQ ID NO:77 Selected from the group consisting of: An antibody or antigen-binding fragment thereof that specifically binds to B-cell maturation antigen (BCMA).

2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:

7.

3. The antibody or antigen-binding fragment thereof of claim 1, wherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 18, and SEQ ID NOs: 115 to 119.

4. The antibody or antigen-binding fragment thereof according to claim 1 , which inhibits binding between a BCMA protein and a substance that specifically binds to the BCMA protein.

5. The antibody or antigen-binding fragment thereof according to claim 4, wherein the substance that specifically binds to the BCMA protein is B cell activating factor (BAFF), proliferation-inducing ligand (APRIL), or a combination thereof.

6. The antigen-binding fragment may be an scFv, (scFv) ２ , Fv, Fab, Fab', F(ab') ２ 2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment is selected from the group consisting of:

7. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is conjugated to an anti-cancer drug.

8. A pharmaceutical composition for preventing or treating cancer, comprising an antibody or an antigen-binding fragment thereof described in any one of claims 1 to 7.

9. The pharmaceutical composition of claim 8, wherein the cancer is multiple myeloma.

Images